The Prognostic and Predictive Role of ATM Expression in Patients with Metastatic Non-Small Cell Lung Cancer Receiving Pembrolizumab Monotherapy or Combination with Chemotherapy

• DOI: 10.20944/preprints202503.1873.v1
• Publication Date: 2025-03-26T05:23:44Z
• Authors: Jamshid Hamdard; Harun Muğlu; Ahmet Bilici; Elif Kuzucular; Özgür Açıkgöz; Ömer Fatih Ölmez; Oktay Olmuşçelik; Özcan Yıldız

Background/Objectives: This study aimed to investigate the prognostic and predictive significance of ATM expression in patients with metastatic non-small cell lung cancer (NSCLC) treated pembrolizumab. Methods: A retrospective analysis was conducted on 49 NSCLC who received first-line pembrolizumab as a single agent or combination chemotherapy. Immunohistochemistry used assess archival pathology specimens. Nuclear staining considered positive. categorized into low high groups based combined score intensity percentage positive cells. Therafter, value evaluated. Results: The median age 64 years (range, 45-81). Most (91.8%) were male. majority (75.5%) had adenocarcinoma. objective response rate (ORR) 69.4%. 75.5% patients. Patients significantly longer progression-free survival (PFS) compared those (51 vs. 5.7 months, p=0.004). In multivariate analysis, only independent factor for PFS. Moreover, shorter overall (OS) 8.9 p=0.013), statistically significant (HR 2.48, p=0.041). Logistic regression showed that associated treatment (p=0.006, OR:0.16, 95% CI: 0.08-0.48), presence bone metastasis absence liver Conclusions: Our findings lower better prognosis response. suggests may be valuable biomarker predicting disease progression